Competence Center for Drug Discovery
The Competence Center for Drug Discovery (CC Drug Discovery) is dedicated to the discovery and development of new drugs for innovative therapies against serious diseases.
The Competence Center for Drug Discovery at the ZHAW works on a national and international level with partners from industry and academia to develop new clinical drug candidates. Our mission is to address therapeutic issues in an interdisciplinary environment and to promote the synergy of biological, chemical and medical expertise. Our core competence in medicinal chemistry enables us to work with our partners on a range of indications (e.g. cancer, infectious diseases, metabolic diseases) for the benefit of patients.
We cover the entire chemistry driven value chain of small molecule and peptide drug discovery:
- Medicinal Chemistry
- Organic Chemistry
- Computer aided drug design
- Natural Products
- Parallel and automated organic synthesis
- Microwave assisted organic synthesis
- NMR binding studies of small molecules
- Recombinant protein production in different expression systems
- Protein characterization
- Microbial and cellular test methods
- Culture Collection of Switzerland (www.ccos.ch)
Therapy for the NRAS melanoma subtype
Melanoma is the fifth most common cancer in Switzerland and the most lethal skin cancer. NRAS (neuroblastoma ras viral oncogene homolog)-mutated melanoma is the most aggressive subtype, with no effective therapy after immunotherapy failure. The goal of this project is to develop the first effective targeted therapy ...
Platform for drug target identification
A major problem in medicinal chemistry and drug discovery projects is the unknown identity of the molecular biological target, even when very potent ligands are available, such as those discovered in a phenotypic screen. Therefore, methods for hit optimization, such as structure-based design, or better understanding ...
Inhibitors targeting SARS-CoV-2 proteases
So far, vaccines are available to combat the Covid-19 pandemic, which can protect against a severe course, although part of society also does not want to be vaccinated or cannot do so due to pre-existing conditions. With a drug that can fight the virus in the organism, infected patients with severe symptoms would be ...
Extracellular vesicles for targeted delivery of new antimicrobials
Infectious disease caused by bacteria constitutes a major threat to human health. Although antibiotics control bacterial infections, their efficacy is mitigated by the rise of antibiotic resistance. Further challenging elimination of pathogenic bacteria, some species such as Staphylococcus aureus, responsible for a ...
- Antiprotozoal Structure–Activity Relationships of Synthetic Leucinostatin Derivatives and Elucidation of their Mode of Action / M. Brand, L. Wang, S. Agnello, S. Gazzola, F. M. Gall, L. Raguž, M. Kaiser, R. S. Schmidt, A. Ritschl, J. Jelk, A. Hemphill, P. Mäser, P. Bütikofer, M. Adams, R. Riedl, Angew. Chem. Int. Ed. 2021, 60, 15613.
- Drug Design Inspired by Nature: Crystallographic Detection of an Auto‐Tailored Protease Inhibitor Template / F. M. Gall, D. Hohl, D. Frasson, T. Wermelinger, P. R. E. Mittl, M. Sievers, R. Riedl, Angew. Chem. Int. Ed. 2019, 58, 4051.
- A Structural View on Medicinal Chemistry Strategies against Drug Resistance / S. Agnello, M. Brand, M. F. Chellat, S. Gazzola, R. Riedl, Angew. Chem. Int. Ed. 2019, 58, 3300.
- Pseudouridimycin: The First Nucleoside Analogue That Selectively Inhibits Bacterial RNA Polymerase / M. F. Chellat, R. Riedl, Angew. Chem. Int. Ed. 2017, 56, 13184.
- Targeting Antibiotic Resistance / Chellat, Mathieu; Raguž, Luka; Riedl, Rainer - Angew. Chem. Int. Ed. 2016, 55, 6600-6626; Angew.Chem. 2016, 128, 6710–6738.
- Molecular recognition of the catalytic zinc (II) ion in MMP-13: Structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies / Fischer, Thomas; Riedl, Rainer - invited article for the Special Issue "Enzyme-Inhibitor Interaction as Examples of Molecular Recognition" Int. J. Mol. Sci. 2016, 17, 314. Front cover story 3/2016.
- Merging Allosteric and Active Site Binding Motifs: De novo Generation of Target Selectivity and Potency via Natural-Product-Derived Fragments / Lanz, Jan; Riedl, Rainer - ChemMedChem. 2015, 10, 451–454. Front cover story 3/2015.
Shrestha, Neeta; Gall, Flavio; Vesin, Jonathan; Chambon, Marc; Turcatti, Gerardo; Fotiadis, Dimitrios; Riedl, Rainer; Plattet, Philippe,
13(1), pp. 128.
Available from: https://doi.org/10.3390/v13010128
Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer,
133(28), pp. 15741-15749.
Available from: https://doi.org/10.1002/ange.202102153
Shrestha, Neeta; Gall, Flavio Max; Mathieu, Cyrille; Hierweger, Melanie Michaela; Brügger, Melanie; Alves, Marco P.; Vesin, Jonathan; Banfi, Damiano; Kalbermatter, David; Horvat, Branka; Chambon, Marc; Turcatti, Gerardo; Fotiadis, Dimitrios; Riedl, Rainer; Plattet, Philippe,
12(6), pp. e0262121.
Available from: https://doi.org/10.1128/mBio.02621-21
Neidhart, Berna; Kowalska, Malwina; Valentin, Jules D. P.; Gall, Flavio; Ren, Qun; Riedl, Rainer; Pot, Simon; Rottmar, Markus,
22(2), pp. 629-639.
Available from: https://doi.org/10.1021/acs.biomac.0c01473